Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

KalVista Pharmaceuticals, Inc. KALV NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
54/100
2/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$32.33
+59.3%

KalVista Pharmaceuticals, Inc. (KALV) is a Biotechnology company in the Healthcare sector, currently trading at $20.29. It has a SharesGrow Score of 52/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is KALV = $32 (+59.3% upside).

Valuation: KALV trades at a trailing Price-to-Earnings (P/E) of -5.9 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.11.

Net income is $183M (loss), growing at -41.1%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $6M against $95M equity (Debt-to-Equity (D/E) ratio 0.07, conservative). Current ratio is 5.35 (strong liquidity). Debt-to-assets is 2.5%. Total assets: $251M.

Analyst outlook: 13 / 13 analysts rate KALV as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 40/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).

$32.33
▲ 59.34% Upside
Average Price Target
Based on 13 Wall Street analysts offering 12-month price targets for KalVista Pharmaceuticals, Inc., the average price target is $32.33, with a high forecast of $37.00, and a low forecast of $28.00.
Highest Price Target
$37.00
Average Price Target
$32.33
Lowest Price Target
$28.00

KALV SharesGrow Score Overview

64/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 40/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — KALV

✓
VALUE Pass
100/100
KALV trades at a trailing Price-to-Earnings (P/E) of -5.9 (S&P 500 average ~25). Forward PEG 0.11 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $32, implying +57.7% from the current price $20. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
KALV: +0%/yr revenue is, -41.1%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet KALV: Debt-to-Equity (D/E) ratio 0.07 (conservative), Current ratio is 5.35 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
40/100
KALV: Gross margin is 0% (+0 pp trend), $1B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 40/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 13 / 13 analysts rate KALV as buy (100%). Analyst consensus target is $32 (+57.7% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range9.235-21.305
Volume1.44M
Avg Volume (30D)924.48K
Market Cap$1.04B
Beta (1Y)-0.40
Share Statistics
EPS (TTM)-3.69
Shares Outstanding$49.65M
IPO Date2015-04-09
Employees150
CEOBenjamin L. Palleiko
Financial Highlights & Ratios
EBITDA$-173.33M
Net Income$-183.44M
Operating Income$-188M
Total Cash$187.65M
Total Debt$6.31M
Net Debt$-92.34M
Total Assets$250.77M
Price / Earnings (P/E)-5.5
Analyst Forecast
1Y Price Target$32.00
Target High$37.00
Target Low$28.00
Upside+57.7%
Rating ConsensusBuy
Analysts Covering13
Buy 100% Hold 0% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS4834971032

Price Chart

Track all markets on TradingView
KALV
KalVista Pharmaceuticals, Inc. ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
9.24 52WK RANGE 21.31

People Also View

KRTX
KRTX
Karuna Therapeutics, Inc.
$329.83
+0.03%
 CYTK
CYTK
Cytokinetics, Incorporated
$66.35
-0.55%
 COGT
COGT
Cogent Biosciences, Inc.
$36.49
-0.08%
 MIRM
MIRM
Mirum Pharmaceuticals, Inc.
$96.90
+0.42%
 CRNX
CRNX
Crinetics Pharmaceuticals, Inc.
$39.75
+2.82%
 EWTX
EWTX
Edgewise Therapeutics, Inc.
$33.16
-2.01%
 DYN
DYN
Dyne Therapeutics, Inc.
$19.81
+4.26%
 DICE
DICE
DICE Therapeutics, Inc.
$47.55
+0.06%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message